<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:46:05Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4608248" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:4608248</identifier>
        <datestamp>2016-03-29</datestamp>
        <setSpec>springeropen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Invest New Drugs</journal-id>
              <journal-id journal-id-type="iso-abbrev">Invest New Drugs</journal-id>
              <journal-title-group>
                <journal-title>Investigational New Drugs</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0167-6997</issn>
              <issn pub-type="epub">1573-0646</issn>
              <publisher>
                <publisher-name>Springer US</publisher-name>
                <publisher-loc>New York</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC4608248</article-id>
              <article-id pub-id-type="pmcid">PMC4608248</article-id>
              <article-id pub-id-type="pmc-uid">4608248</article-id>
              <article-id pub-id-type="pmid">26123926</article-id>
              <article-id pub-id-type="pmid">26123926</article-id>
              <article-id pub-id-type="publisher-id">269</article-id>
              <article-id pub-id-type="doi">10.1007/s10637-015-0269-8</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Phase II Studies</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Tolaney</surname>
                    <given-names>Sara M.</given-names>
                  </name>
                  <address>
                    <phone>617-632-5743</phone>
                    <email>stolaney@partners.org</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tan</surname>
                    <given-names>Sally</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Guo</surname>
                    <given-names>Hao</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Barry</surname>
                    <given-names>William</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Van Allen</surname>
                    <given-names>Eliezer</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wagle</surname>
                    <given-names>Nikhil</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1"/>
                  <xref ref-type="aff" rid="Aff4"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Brock</surname>
                    <given-names>Jane</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff5"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Larrabee</surname>
                    <given-names>Katherine</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Paweletz</surname>
                    <given-names>Cloud</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1"/>
                  <xref ref-type="aff" rid="Aff6"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ivanova</surname>
                    <given-names>Elena</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1"/>
                  <xref ref-type="aff" rid="Aff6"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Janne</surname>
                    <given-names>Pasi</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1"/>
                  <xref ref-type="aff" rid="Aff6"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Overmoyer</surname>
                    <given-names>Beth</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wright</surname>
                    <given-names>John J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff7"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Shapiro</surname>
                    <given-names>Geoffrey I.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Winer</surname>
                    <given-names>Eric P.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Krop</surname>
                    <given-names>Ian E.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1"/>
                </contrib>
                <aff id="Aff1"><label/>Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Yawkey 1257, Boston, MA 02215 USA </aff>
                <aff id="Aff2"><label/>Harvard Medical School, Boston, MA USA </aff>
                <aff id="Aff3"><label/>Department of Biostatistics and Computation Biology, Dana-Farber Cancer Institute, Boston, MA USA </aff>
                <aff id="Aff4"><label/>Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA USA </aff>
                <aff id="Aff5"><label/>Department of Pathology, Brigham and Women’s Hospital, Boston, MA USA </aff>
                <aff id="Aff6"><label/>Belfer Institute for Applied Cancer Sciences, Dana-Farber Cancer Institute, Boston, MA USA </aff>
                <aff id="Aff7"><label/>Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>1</day>
                <month>7</month>
                <year>2015</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>1</day>
                <month>7</month>
                <year>2015</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <year>2015</year>
              </pub-date>
              <volume>33</volume>
              <fpage>1108</fpage>
              <lpage>1114</lpage>
              <history>
                <date date-type="received">
                  <day>8</day>
                  <month>6</month>
                  <year>2015</year>
                </date>
                <date date-type="accepted">
                  <day>19</day>
                  <month>6</month>
                  <year>2015</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2015</copyright-statement>
                <license license-type="OpenAccess">
                  <license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <title>Summary</title>
                <p><italic>Background</italic> MET expression and activation appear to be important for initiation and progression of triple-negative breast cancer. Tivantinib (ARQ 197) is an orally administered agent that targets MET, although recent preclinical data suggests the agent may have mechanisms of action that are independent of MET signaling. We conducted a phase 2 study of tivantinib monotherapy in patients with metastatic triple-negative breast cancer. <italic>Methods</italic> Patients with metastatic triple-negative breast cancer who had received 1 to 3 prior lines of chemotherapy in the metastatic setting were enrolled into this two-stage, single arm phase 2 study. Treatment consisted of twice daily oral dosing of tivantinib (360 mg po bid) during a 21-day cycle. Patients underwent restaging scans at 6 weeks, and then every 9 weeks. Tumor biomarkers that might predict response to tivantinib were explored. <italic>Results</italic> 22 patients were enrolled. The overall response rate was 5 % (95 % CI 0–25 %) and the 6-month progression-free survival (PFS) was 5 % (95 % CI 0–25 %), with one patient achieving a partial response (PR). Toxicity was minimal with only 5 grade ≥3 adverse events (one grade 3 anemia, one grade 3 fatigue, and 3 patients with grade 3/4 neutropenia). <italic>Conclusion</italic> This study represents the first evaluation of tivantinib for the treatment of metastatic triple-negative breast cancer. These results suggest that single agent tivantinib is well tolerated, but did not meet prespecified statistical targets for efficacy.</p>
              </abstract>
              <kwd-group xml:lang="en">
                <title>Keywords</title>
                <kwd>Triple-negative breast cancer</kwd>
                <kwd>Tivantinib</kwd>
                <kwd>MET</kwd>
                <kwd>ARQ 197</kwd>
              </kwd-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© Springer Science+Business Media New York 2015</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1" sec-type="introduction">
              <title>Introduction</title>
              <p>Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer death in American women [<xref ref-type="bibr" rid="CR1">1</xref>]. Despite recent advances in breast cancer treatment, metastatic disease remains incurable. One possible limitation of current therapies has been an inability to select subsets of patients most likely to benefit from specific agents. With the application of gene expression array technology, the heterogeneity of breast cancer has become clearer and the identification of novel cancer subtypes has reinvigorated the search for more specific and effective treatments. Hierarchical clustering of genomic expression data from breast cancer specimens has demonstrated several distinct tumor subgroups with unique expression profiles, including a HER2-positive subgroup, two estrogen-receptor (ER) driven groups, and a “basal-like” group [<xref ref-type="bibr" rid="CR2">2</xref>]. The basal-like tumors have a poor prognosis relative to other subtypes, even with the best available therapy. Approximately 10–15 % of individuals with breast cancer have basal-like disease [<xref ref-type="bibr" rid="CR3">3</xref>]. While not all basal-like cancers are triple-negative breast cancers, the majority of triple-negative breast cancers have a basal-like phenotype. There are currently no U.S. Food and Drug Administration (FDA)-approved agents for specific management of triple-negative breast cancer, and there is significant need to develop rational therapy for this subtype of the disease.</p>
              <p>MET is a membrane receptor normally expressed on cells of epithelial origin. Hepatocyte growth factor (HGF) is the only known ligand of the MET receptor. Upon HGF stimulation, MET induces several biologic responses that lead to invasive growth. MET overexpression, with or without gene amplification, has been reported in a variety of malignancies, including breast, colorectal, lung, gastric, and hepatocellular carcinoma [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Elevated expression of MET has been associated with poor prognosis in breast cancer [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Interestingly, data suggest that hepatocyte growth factor (HGF), the ligand for MET, and MET are expressed to a greater degree in triple-negative breast cancer relative to other breast cancer subtypes [<xref ref-type="bibr" rid="CR8">8</xref>–<xref ref-type="bibr" rid="CR11">11</xref>]. Mouse models also suggest a critical role for the MET pathway during the development of triple-negative breast cancer. Mice harboring an activating mutant MET knock-in or mutant MET transgene under mouse mammary tumor virus promoter, develop breast cancers with a triple-negative phenotype [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Additionally, a MET-driven pathway gene expression signature clustered with basal and triple-negative breast cancer from human tissue samples and correlated with worse patient outcome [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. These studies suggest that MET expression and activation are important for initiation and progression of triple-negative breast cancer.</p>
              <p>Early preclinical work suggested that tivantinib (ARQ 197) binds to and inhibits MET in vitro, and phase I and II trials in a variety of malignancies demonstrated the safety and tolerability of tivantinib, and suggested promising activity of this agent [<xref ref-type="bibr" rid="CR14">14</xref>–<xref ref-type="bibr" rid="CR17">17</xref>]. Because MET expression is increased in the triple-negative subset of breast cancer and is associated with worse prognosis, targeting MET signaling in this population is a rational therapeutic strategy. We therefore conducted a single-arm phase 2 study of tivantinib monotherapy in unselected patients with metastatic triple-negative breast cancer.</p>
            </sec>
            <sec id="Sec2" sec-type="materials|methods">
              <title>Patients and methods</title>
              <sec id="Sec3">
                <title>Patient eligibility</title>
                <p>Patients ≥18 years of age with measurable metastatic triple-negative breast cancer were eligible. Triple-negative status was defined as estrogen receptor negative (&lt;10 % staining by immunohistochemistry (IHC)), progesterone receptor negative (&lt;10 % staining by IHC), and HER2-negative (0 or 1+ by IHC, or FISH &lt;2.0). Patients may have received 1 to 3 prior chemotherapeutic regimens for metastatic breast cancer, and must have been off treatment for 14 days prior to initiation of study treatment. Patients must have recovered from acute toxicities of their prior treatment. Patients may have received prior radiation therapy in either the metastatic or early-stage setting, but radiation was required to be completed at least 14 days prior to initiation of study treatment. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status ≤2, and a projected life expectancy greater than 6 months. They were also required to provide formalin-fixed, paraffin-embedded (FFPE) tumor tissue. Key exclusion criteria included: prior receipt of a MET inhibitor; known brain metastases that are untreated, symptomatic, or require therapy to control symptoms; and QTc &gt; 470 ms. Research was approved by local human research protections programs and institutional review boards, and studies were conducted in accordance with the Declaration of Helsinki.</p>
              </sec>
              <sec id="Sec4">
                <title>Study design and treatment</title>
                <p>This was a single-arm, two-stage phase 2 study assessing the efficacy of tivantinib monotherapy in patients with metastatic triple-negative breast cancer. Tivantinib was provided by Daiichi Sankyo/ArQule through the Cooperative Research and Development Agreement (CRADA) program. Treatment consisted of oral dosing of tivantinib at 360 mg twice daily over a 21-day cycle. Patients underwent radiographic restaging at 6 weeks, and then every 9 weeks. Patients with complete or partial RECIST responses continued to receive study treatment, while those with progressive disease were taken off study. Dose reductions for toxicity occurred if patients experienced grade 3 or 4 neutropenia or non-hematologic adverse events. From the starting dose of 360 mg, doses were reduced as needed to 240 mg twice daily, 120 mg twice daily, and 120 mg once daily.</p>
                <p>The primary objective of this study was to evaluate the activity of tivantinib, as defined by 6-month progression-free survival (PFS) in patients with metastatic triple-negative breast cancer. The 6-month progression-free survival (PFS) was defined as the proportion of patients still receiving treatment at 6 months, who were alive and free of progression at this time point. Secondary objectives were to evaluate objective response based on RECIST 1.1 criteria, to evaluate MET and phospho-MET expression in archival tumor tissue, and to evaluate the incidence of MET positive circulating tumor cells (CTCs) at baseline.</p>
              </sec>
              <sec id="Sec5">
                <title>Assessment of MET amplification by fluorescence in situ hybridization (FISH) in tissue</title>
                <p>MET FISH probe labeled with SpectrumRed and CEP7 reference probe labeled with SpectrumGreen were purchased from Abbott Molecular (Des Plaines, IL). FISH was performed following standard protocols. Briefly, 5 μm tissue slides were baked overnight at 60 °C, deparaffinized, treated in 1 % sodium borohydride for 4 h and heated in pressure cooker for 20 min in citrate buffer (pH = 6). After treatment with 150 μg/ml solution of Proteinase K, slides were fixed in 1 % neutral-buffered formalin and denatured in 70 % formamide for 4 min at 72 °C. Probe was denatured for 5 min at 80 °C and incubated for 30 min at 37 °C for pre-annealing. Hybridization was carried out overnight at 37 °C; post-hybridization slide washes were carried out for 20 min in 50 % formamide/2xSSC at 45 °C, followed by 5 min wash in 1 × SSC at 45 °C. FISH signal evaluation and acquisition were performed manually using filter sets and software developed by Applied Spectral Imaging (Carlsbad, CA). Several fields with at least 50 tumor cells total were captured and ratio of MET to CEP7 signal numbers was calculated. Assessment of ploidy status was done by visual screening of all tumor area; cells with maximum number of signals were recorded. MET amplification was defined as a MET/CEP7 ratio ≥ 2. Samples having a MET/CEP7 ratio from 1.5 and up to 2 were defined as having relative MET gain. Samples with a MET/CEP7 ratio of 1 but with more than two copies of each probe were defined as having polysomy of chromosome 7.</p>
              </sec>
              <sec id="Sec6">
                <title>Assessment of MET amplification in circulating tumor cells</title>
                <p>CTCs were enriched from 7.5 mL of a patient’s whole blood at the Circulating Tumor Cell Core Facility (Brigham and Women’s Hospital, Boston, MA) using the Circulating Tumor Cell Profile Kit (Veridex/Janssen Diagnostics, Raritan, NJ). Processed samples were received as cells suspended in 900 uL of buffer. An equal volume of PBS was added before tubes were spun down at 200 × g for 8 min. Supernatant was carefully removed, leaving approximately 60 uL of buffer. Cell pellets were gently resuspended and the suspension was applied on the labeled slide and allowed to dry in the vacuum desiccators at room temperature. Slides were placed in methanol at −20 °C for aging and storage.</p>
                <p>For FISH, dried slides were treated in 2 × SSC at 37 °C for 30 min, followed by 10 min of treatment with 0.002 % pepsin solution in 0.01 M HCl at 37 °C and 15 min of fixation in 1 % formalin at room temperature. Slides were dehydrated in the series of ethanols, dried and co-denatured with MET/CEP7 FISH probe (Kreatech/Leica Microsystems Inc., Buffalo Grove, IL) on an 80 °C plate for 2 min. Hybridization was carried out at 37 °C overnight, followed by a 0.4xSSC/0.3 % Igepal wash at 72 °C for 3 min and a 2 × SSC/0.1 % Igepal wash at room temperature for 1 min. Slides were dehydrated in the series of ethanols, and dried before application of Vectashield mounting medium with DAPI (Vector Laboratories Inc., Burlingame, CA). FISH signal evaluation and acquisition were performed manually using filter sets and software developed by Applied Spectral Imaging (Carlsbad, CA).</p>
              </sec>
              <sec id="Sec7">
                <title>Immunohistochemistry biomarker assays</title>
                <p>Available archival tumor tissue was tested centrally for MET and phospho-MET protein expression. Four-micrometer-thick sections were baked at 37 °C overnight, then deparaffinized and rehydrated. Endogenous peroxidase activity was blocked with 3 % hydrogen peroxide in methanol. For heat induced epitope retrieval, slides were placed in 10 mmol/L citrate buffer at a pH of 6.0 (Target Retrieval Solution, S1699, DAKO) and then pressure cooked (Biocare Medical, Concord, CA) at 122 °C to between 14 and 17 psi with the cycle lasting, on average, 45 min and a cool-down period of approximately 20 min. Immunostains were performed on an automated instrument (DAKO Autostainer Plus, DAKO). A range of titers was tested for both antibodies, and titers were calibrated using positive control staining. Primary antibodies to MET, clone SP44 (dilution 1:100; Spring Bioscience), phospo-MET, clone Y1234/1235 (dilution 1:50; Cell Signaling) were incubated for 40 min at room temperature. A DAKO polymer secondary antibody system was used (EnVision + System-HRP; DAKO, Carpinteria, CA) and incubated for 30 min in a humid chamber at room temperature. Sections were developed using 3,3-diaminobenzidine (Sigma Chemical, St Louis, MO) as substrate and counterstained with Mayer hematoxylin. External positive controls were also run.</p>
                <p>MET and phospho-MET protein expression levels were recorded as percentages of positively stained tumor cells in each of the five intensity categories denoted as zero (no staining), 1+ (weak but detectable), 2+ (mildly distinct), 3+ (moderately distinct) and 4+ (strong). For each tumor, a value was derived by summing up the percentages of cells staining at each intensity, multiplied by the weighted intensity of staining: H-Score = (0 × % at 0) + (1× % at 1+) + (2× % at 2+) + (3× % at 3+). This score produces a continuous variable that ranges from 0 to 300. A positive result was set to an H-Score of 1, defined as a minimum of 1 % of tumor cells staining weakly 1+ [<xref ref-type="bibr" rid="CR18">18</xref>].</p>
              </sec>
              <sec id="Sec8">
                <title>Whole exome sequencing protocol</title>
                <p>In the patient who achieved a RECIST response, tumor and matched germline tissue underwent DNA extraction and whole exome sequencing, using a previously described protocol [<xref ref-type="bibr" rid="CR19">19</xref>]. After whole exome sequencing, somatic point mutations were identified using MuTect [<xref ref-type="bibr" rid="CR20">20</xref>]. A heuristic algorithm was then applied to identify somatic variants that may have clinical or biological relevance for the selected patient samples.</p>
              </sec>
            </sec>
            <sec id="Sec9" sec-type="materials|methods">
              <title>Statistical methods</title>
              <p>This study used a Simon optimal two-stage design to control type I error at 10 % and have at least 90 % power to detect the acceptable response rate. The sample size was calculated to distinguish between a response rate of 10 versus 31 %. In the study design, 13 participants were to be enrolled in the first stage. If there were at least 2 participants who were alive and progression free at 6 months, the study would enroll another 13 participants. If there were 4 or fewer of the 26 who were alive and progression-free at 6 months, the regimen would be declared inactive. If there were 5 or more who were alive and progression-free at 6 months, the regimen would be declared active. PFS and 95 % confidence intervals (CIs) are described using Kaplan-Meier methods. The overall response is tabulated. All correlative analyses are exploratory.</p>
            </sec>
            <sec id="Sec10" sec-type="results">
              <title>Results</title>
              <p>The study was activated in April 2012. Based on slow accrual and external findings suggesting that tivantinib may not actually inhibit MET [<xref ref-type="bibr" rid="CR21">21</xref>], accrual to the study closed in July 2013 after a total of 22 patients were enrolled.</p>
              <sec id="Sec11">
                <title>Patient characteristics</title>
                <p>The baseline characteristics of the patients enrolled into the study are listed in Table <xref rid="Tab1" ref-type="table">1</xref>. The mean age was 55 and patients had received a median of 2 prior lines of chemotherapy for metastatic disease. Most patients had widespread metastatic disease, with 73 % of participants having at least 3 metastatic sites, the most common of which were regional lymph nodes (14 of 22 patients), ipsilateral skin of breast/chest wall (11 of 22 patients), bone (10 of 22 patients) and lung (10 of 22 patients).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline patient characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th>Number</th><th>Percent</th></tr></thead><tbody><tr><td colspan="3">Age</td></tr><tr><td> Mean (SD)</td><td>55 (10)</td><td>–</td></tr><tr><td> Median (Range)</td><td>56 (33–73)</td><td>–</td></tr><tr><td colspan="3">Race</td></tr><tr><td> White</td><td>20</td><td>91</td></tr><tr><td> Black or African American</td><td>2</td><td>9</td></tr><tr><td colspan="3">Number of metastatic sites</td></tr><tr><td> 1</td><td>3</td><td>14</td></tr><tr><td> 2</td><td>3</td><td>14</td></tr><tr><td>  ≥ 3</td><td>16</td><td>72</td></tr><tr><td colspan="3">ECOG performance status</td></tr><tr><td> 0</td><td>16</td><td>73</td></tr><tr><td> 1</td><td>6</td><td>27</td></tr><tr><td colspan="3">Prior lines of chemotherapy for metastatic breast cancer</td></tr><tr><td> 1</td><td>8</td><td>36</td></tr><tr><td> 2</td><td>10</td><td>46</td></tr><tr><td> 3</td><td>4</td><td>18</td></tr></tbody></table></table-wrap></p>
              </sec>
              <sec id="Sec12">
                <title>Response to therapy</title>
                <p>In all patients, the median progression-free survival (PFS) was 1.2 months (95 % CI: 1.0–1.4), Fig. <xref rid="Fig1" ref-type="fig">1</xref>. Only one patient had PFS &gt; 6 months (4.5 %, 95 % CI: 0.2–24.7 %). This patient had disease involving her chest wall, lymph nodes, and pleura. She had a progression free interval of 7.8 months, and progression occurred at a regional lymph node. This patient also achieved a partial reponse (PR). Although the study did not meet the prespecified threshold for continuation, the observation of one partial responder with a PFS &gt; 6 months led the study team to continue accrual to the second stage to further characterize the activity. The overall response rate was 4.5 % (95 % CI 0.1–22.8 %) (Table <xref rid="Tab2" ref-type="table">2</xref>). There were 6 patients (27.3 %) with stable disease as the best overall response by RECIST 1.1. Based on external findings about the mechanism of action of tivantinib [<xref ref-type="bibr" rid="CR21">21</xref>], and the fact that only 1 patient achieved a PFS &gt; 6 months, accrual to the study closed in July 2013 after a total of 22 patients were enrolled.<fig id="Fig1"><label>Fig. 1</label><caption><p>Progression-free survival curves depicting final response to therapy</p></caption><graphic xlink:href="10637_2015_269_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab2"><label>Table 2</label><caption><p>Response rates to tivantinib therapy</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Best overall response</th><th>Number</th><th>Percent</th></tr></thead><tbody><tr><td>Partial response</td><td>1</td><td char="." align="char">4.5</td></tr><tr><td>Stable disease</td><td>6</td><td char="." align="char">27.3</td></tr><tr><td>Progressive disease</td><td>15</td><td char="." align="char">68.2</td></tr></tbody></table></table-wrap></p>
              </sec>
              <sec id="Sec13">
                <title>Toxicity</title>
                <p>Few severe adverse events were reported by patients taking tivantinib (Table <xref rid="Tab3" ref-type="table">3</xref>). Of the 46 adverse events reported, 41 were of grade 1 or 2. The most common adverse event was fatigue. There were only 5 grade ≥3 adverse events (one grade 3 anemia, one grade 3 fatigue, and 3 patients experienced grade 3/4 neutropenia).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Maximum grade reported for agent specific adverse events</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Adverse events</th><th>Grade 1</th><th>Grade 2</th><th>Grade 3</th><th>Grade 4</th><th>Total # of patients (%)</th></tr></thead><tbody><tr><td>Fatigue</td><td>10</td><td>5</td><td>1</td><td>0</td><td>16 (73 %)</td></tr><tr><td>Nausea</td><td>7</td><td>0</td><td>0</td><td>0</td><td>7 (32 %)</td></tr><tr><td>Anemia</td><td>2</td><td>3</td><td>1</td><td>0</td><td>6 (27 %)</td></tr><tr><td>Diarrhea</td><td>4</td><td>2</td><td>0</td><td>0</td><td>6 (27 %)</td></tr><tr><td>Neutropenia</td><td>2</td><td>0</td><td>2</td><td>1</td><td>5 (23 %)</td></tr><tr><td>Anorexia</td><td>2</td><td>2</td><td>0</td><td>0</td><td>4 (18 %)</td></tr><tr><td>Rash maculo-papular</td><td>3</td><td>0</td><td>0</td><td>0</td><td>3 (14 %)</td></tr><tr><td>Vomiting</td><td>2</td><td>0</td><td>0</td><td>0</td><td>2 (9 %)</td></tr></tbody></table></table-wrap></p>
                <p>Four dose reductions occurred in 2 patients due to neutropenia and fatigue. Three of four dose reductions occurred within the first two cycles. The one responder required two dose reductions, one in cycle 2 (neutropenia) and another in cycle 8 (neutropenia and fatigue).</p>
              </sec>
              <sec id="Sec14">
                <title>MET expression studies</title>
                <p>All 22 enrolled patients had adequate amounts of archival tissue for immunohistochemical (IHC) staining. Among those 22 patients, 10 had positive IHC staining for MET (H-score: median 5, range 1–35), while none of the patients had positive phospho-MET staining on archival tumor tissue. Of 7 patients with circulating tumor cells (CTCs) collected at baseline, 1 had 2-fold MET amplification in her CTCs as assessed by FISH, but this was not correlated with response, as the patient had progressive disease at the first 6 week restaging. Of 18 patients who had FISH testing for MET on archival tissue, 3 were amplified in &lt;5 % of nuclei. Four patients did not have adequate amounts of archival tissue for FISH analysis. The one responder was negative for MET and phospho-MET by IHC on archival tissue, and had CTCs that were not MET-amplified. Her archival tumor tissue was amplified for MET by FISH in less than 2 % of nuclei, though the clinical significance of this is unclear (Fig. <xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>FISH analysis of MET gene on archival tissue of patient with partial response. Most of the 100–120 cells analyzed had ploidy level up to 4n, and the two (~2 % of cells) illustrated below had MET copy number increase (1.5-fold gain and 3.5-fold amplification, respectively)</p></caption><graphic xlink:href="10637_2015_269_Fig2_HTML" id="MO2"/></fig></p>
              </sec>
              <sec id="Sec15">
                <title>Whole exome sequencing</title>
                <p>Whole exome sequencing of archival tumor tissue and tissue from time of progression in the patient who experienced a PR was attempted. The mean target coverage of the progresion tumor sample was 117 ×. In this sample, somatic mutations in known breast cancer genes MAP2K4 (H79R) and TP53 (R110P) were identified, as well as a variant of unknown significance in the kinase domain of JAK2 (E577Q). No alterations that suggest a mechanism of response or resistance to this agent were found. Unfortunately, this patient’s baseline tumor was unevaluable using this sequencing technology, so it was not possible to determine whether any changes in mutational status led to development of tivantinib resistance.</p>
              </sec>
            </sec>
            <sec id="Sec16" sec-type="discussion">
              <title>Discussion</title>
              <p>This trial represents the first study of tivantinib for the treatment of metastatic triple-negative breast cancer. Of 22 patients that were evaluated, only one patient had an objective response. The single responder did not have evidence of MET expression by IHC or clear evidence of MET amplification in her archival tumor specimen, so it is unclear if her response was due to inhibition of MET. To further understand the molecular rationale for the one responder to tivantinib in our trial, we performed whole exome sequencing on tissue from her post-progression biopsy. This analysis identified mutations in known breast cancer genes MAP2K4 and TP53, as well as a mutation in the kinase domain of JAK2. However, the patient’s archival tumor tissue sample was unevaluable, so we could not compare the mutational profile of tivantinib-sensitive versus resistant tissue.</p>
              <p>One potential explanation for the low response rate seen in this study was that the population was not enriched for patients with tumors that were high in MET overexpression. Prospective data from studies of tivantinib in the treatment of hepatocellular carcinoma found that positive MET expression (≥2+ staining in ≥50 % of tumor cells by IHC) was associated with improved overall survival (OS), PFS, and time to progression [<xref ref-type="bibr" rid="CR22">22</xref>]. Additionally, in the MARQUEE trial for patients with advanced non-small cell lung cancer, an exploratory analysis found that patients with tumor that were at least 2+ positive for MET by IHC in more than 50 % of tumor cell experienced longer PFS and OS with combined MET-EGFR inhibition while in patients with MET-low tumors, tivantinib did not improve OS compared to placebo [<xref ref-type="bibr" rid="CR23">23</xref>]. These data suggest that benefit from tivantinib may potentially be restricted largely to patients with significant MET overexpression, and none of the patients in our study had MET overexpressed in greater than 50 % of the tumor. This may be because MET expression diminishes over time after slides have been cut from paraffin-embedded blocks [<xref ref-type="bibr" rid="CR24">24</xref>]. For all our patients, samples were analyzed in batch at the end of the clinical trial. Therefore false negativity of samples tested in this study cannot be excluded. Alternatively, it may also be that this level of MET overexpression is uncommon in TNBC. In a randomized phase 2 study evaluating onartuzumab, a monoclonal antibody directed against MET, only 12 % of patients with TNBC had moderate to high expression of MET (IHC 2+/3+ in 50 % of stained tumor cells) [<xref ref-type="bibr" rid="CR25">25</xref>]. Interestingly, the addition of onartuzumab to either paclitaxel and bevacizumab or paclitaxel alone did not improve PFS or OS compared with paclitaxel and bevacizumab in patients with metastatic or locally recurrent TNBC; additionally, the efficacy in the MET-positive and MET-negative subgroups was similar.</p>
              <p>The low response rate in this study may also be related to the possibility that tivantinib may not be a specific inhibitor of MET. Pre-clinical work has revealed that tivantinib binds to MET in vitro, in vivo, and demonstrated disease regression in phase I, II, and III clinical trials [<xref ref-type="bibr" rid="CR14">14</xref>–<xref ref-type="bibr" rid="CR17">17</xref>]. However, while the current study was ongoing, several preclinical studies were published suggesting that tivantinib’s mechanism of action may be via anti-tubulin cytotoxic activity. Basilico et al. [<xref ref-type="bibr" rid="CR26">26</xref>], Katayama et al. [<xref ref-type="bibr" rid="CR27">27</xref>], and Calles et al. [<xref ref-type="bibr" rid="CR28">28</xref>] compared the pharmacological profile of tivantinib with that of other selective MET inhibitors in a large panel of human tumor cell lines. They found that tivantinib indiscriminately caused cell death on all actively mitotic tumor cells, regardless of MET gene copy number and MET protein expression. Tivantinib also induced apoptosis in both MET-negative tumor cells and genetically engineered cancer cells expressing a MET protein lacking the tivantinib-binding domain, suggesting that tivantinib acts independently of its ability to bind MET [<xref ref-type="bibr" rid="CR26">26</xref>]. More recently, data suggests that cytoskeletal and apoptotic changes in cells treated with tivantinib may be mediated by paxilin, a cytoskeleton regulator controlled by MET [<xref ref-type="bibr" rid="CR3">3</xref>].</p>
              <p>While the reason for the low response rate seen in this study is not clear, our results indicate that though tivantinib is well tolerated, it does not have significant clinical efficacy when used as monotherapy to treat unselected, metastatic triple-negative breast cancer.</p>
            </sec>
          </body>
          <back>
            <ack>
              <p>This work was supported by the Cancer Therapy Evaluation Program (CTEP) of the Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI) through grant number NCT01575522 as well as the Susan F. Smith Executive Council Fund. We thank Carrie Sougnez and the Broad Genomics Platform for sequencing and analysis collaborations.</p>
              <sec id="FPar1">
                <title>Conflict of interest</title>
                <p>The authors declare that they have no conflict of interest.</p>
              </sec>
            </ack>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Siegel</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Ma</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Zou</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Jemal</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>Cancer statistics, 2014</article-title>
                  <source>CA Cancer J Clin</source>
                  <year>2014</year>
                  <volume>64</volume>
                  <issue>1</issue>
                  <fpage>9</fpage>
                  <lpage>29</lpage>
                  <pub-id pub-id-type="doi">10.3322/caac.21208</pub-id>
                  <?supplied-pmid 24399786?>
                  <pub-id pub-id-type="pmid">24399786</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Perou</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Sorlie</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Eisen</surname>
                      <given-names>MB</given-names>
                    </name>
                    <name>
                      <surname>van de Rijn</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Jeffrey</surname>
                      <given-names>SS</given-names>
                    </name>
                    <name>
                      <surname>Rees</surname>
                      <given-names>CA</given-names>
                    </name>
                    <name>
                      <surname>Pollack</surname>
                      <given-names>JR</given-names>
                    </name>
                    <name>
                      <surname>Ross</surname>
                      <given-names>DT</given-names>
                    </name>
                    <name>
                      <surname>Johnsen</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Akslen</surname>
                      <given-names>LA</given-names>
                    </name>
                    <name>
                      <surname>Fluge</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Pergamenschikov</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Williams</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Zhu</surname>
                      <given-names>SX</given-names>
                    </name>
                    <name>
                      <surname>Lonning</surname>
                      <given-names>PE</given-names>
                    </name>
                    <name>
                      <surname>Borresen-Dale</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Brown</surname>
                      <given-names>PO</given-names>
                    </name>
                    <name>
                      <surname>Botstein</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>Molecular portraits of human breast tumours</article-title>
                  <source>Nature</source>
                  <year>2000</year>
                  <volume>406</volume>
                  <issue>6797</issue>
                  <fpage>747</fpage>
                  <lpage>752</lpage>
                  <pub-id pub-id-type="doi">10.1038/35021093</pub-id>
                  <?supplied-pmid 10963602?>
                  <pub-id pub-id-type="pmid">10963602</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Eroles</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Bosch</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Perez-Fidalgo</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Lluch</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>Molecular biology in breast cancer: intrinsic subtypes and signaling pathways</article-title>
                  <source>Cancer Treat Rev</source>
                  <year>2012</year>
                  <volume>38</volume>
                  <issue>6</issue>
                  <fpage>698</fpage>
                  <lpage>707</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ctrv.2011.11.005</pub-id>
                  <?supplied-pmid 22178455?>
                  <pub-id pub-id-type="pmid">22178455</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Boix</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Rosa</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Ventura</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Castells</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Bruix</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Rodes</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Bartrons</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <article-title>c-met mRNA overexpression in human hepatocellular carcinoma</article-title>
                  <source>Hepatology</source>
                  <year>1994</year>
                  <volume>19</volume>
                  <issue>1</issue>
                  <fpage>88</fpage>
                  <lpage>91</lpage>
                  <pub-id pub-id-type="doi">10.1002/hep.1840190115</pub-id>
                  <?supplied-pmid 8276372?>
                  <pub-id pub-id-type="pmid">8276372</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kuniyasu</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Yasui</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Yokozaki</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Kitadai</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Tahara</surname>
                      <given-names>E</given-names>
                    </name>
                  </person-group>
                  <article-title>Aberrant expression of c-met mRNA in human gastric carcinomas</article-title>
                  <source>Int J Cancer</source>
                  <year>1993</year>
                  <volume>55</volume>
                  <issue>1</issue>
                  <fpage>72</fpage>
                  <lpage>75</lpage>
                  <pub-id pub-id-type="doi">10.1002/ijc.2910550114</pub-id>
                  <?supplied-pmid 8344755?>
                  <pub-id pub-id-type="pmid">8344755</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kang</surname>
                      <given-names>JY</given-names>
                    </name>
                    <name>
                      <surname>Dolled-Filhart</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Ocal</surname>
                      <given-names>IT</given-names>
                    </name>
                    <name>
                      <surname>Singh</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Lin</surname>
                      <given-names>CY</given-names>
                    </name>
                    <name>
                      <surname>Dickson</surname>
                      <given-names>RB</given-names>
                    </name>
                    <name>
                      <surname>Rimm</surname>
                      <given-names>DL</given-names>
                    </name>
                    <name>
                      <surname>Camp</surname>
                      <given-names>RL</given-names>
                    </name>
                  </person-group>
                  <article-title>Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer</article-title>
                  <source>Cancer Res</source>
                  <year>2003</year>
                  <volume>63</volume>
                  <issue>5</issue>
                  <fpage>1101</fpage>
                  <lpage>1105</lpage>
                  <?supplied-pmid 12615728?>
                  <pub-id pub-id-type="pmid">12615728</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lengyel</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Prechtel</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Resau</surname>
                      <given-names>JH</given-names>
                    </name>
                    <name>
                      <surname>Gauger</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Welk</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Lindemann</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Salanti</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Richter</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Knudsen</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Vande Woude</surname>
                      <given-names>GF</given-names>
                    </name>
                    <name>
                      <surname>Harbeck</surname>
                      <given-names>N</given-names>
                    </name>
                  </person-group>
                  <article-title>C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu</article-title>
                  <source>Int J Cancer</source>
                  <year>2005</year>
                  <volume>113</volume>
                  <issue>4</issue>
                  <fpage>678</fpage>
                  <lpage>682</lpage>
                  <pub-id pub-id-type="doi">10.1002/ijc.20598</pub-id>
                  <?supplied-pmid 15455388?>
                  <pub-id pub-id-type="pmid">15455388</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Camp</surname>
                      <given-names>RL</given-names>
                    </name>
                    <name>
                      <surname>Rimm</surname>
                      <given-names>EB</given-names>
                    </name>
                    <name>
                      <surname>Rimm</surname>
                      <given-names>DL</given-names>
                    </name>
                  </person-group>
                  <article-title>Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma</article-title>
                  <source>Cancer</source>
                  <year>1999</year>
                  <volume>86</volume>
                  <issue>11</issue>
                  <fpage>2259</fpage>
                  <lpage>2265</lpage>
                  <pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(19991201)86:11&lt;2259::AID-CNCR13&gt;3.0.CO;2-2</pub-id>
                  <?supplied-pmid 10590366?>
                  <pub-id pub-id-type="pmid">10590366</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sheen-Chen</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>YW</given-names>
                    </name>
                    <name>
                      <surname>Eng</surname>
                      <given-names>HL</given-names>
                    </name>
                    <name>
                      <surname>Chou</surname>
                      <given-names>FF</given-names>
                    </name>
                  </person-group>
                  <article-title>Serum levels of hepatocyte growth factor in patients with breast cancer</article-title>
                  <source>Cancer Epidemiol Biomarkers Prev</source>
                  <year>2005</year>
                  <volume>14</volume>
                  <issue>3</issue>
                  <fpage>715</fpage>
                  <lpage>717</lpage>
                  <pub-id pub-id-type="doi">10.1158/1055-9965.EPI-04-0340</pub-id>
                  <?supplied-pmid 15767355?>
                  <pub-id pub-id-type="pmid">15767355</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Andrulis</surname>
                      <given-names>IL</given-names>
                    </name>
                    <name>
                      <surname>Bull</surname>
                      <given-names>SB</given-names>
                    </name>
                    <name>
                      <surname>Blackstein</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Sutherland</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Mak</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Sidlofsky</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Pritzker</surname>
                      <given-names>KP</given-names>
                    </name>
                    <name>
                      <surname>Hartwick</surname>
                      <given-names>RW</given-names>
                    </name>
                    <name>
                      <surname>Hanna</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Lickley</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Wilkinson</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Qizilbash</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Ambus</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>Lipa</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Weizel</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Katz</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Baida</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Mariz</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Stoik</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Dacamara</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Strongitharm</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Geddie</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>McCready</surname>
                      <given-names>D</given-names>
                    </name>
                    <collab>Toronto Breast Cancer Study Group</collab>
                  </person-group>
                  <article-title>neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer</article-title>
                  <source>J Clin Oncol</source>
                  <year>1998</year>
                  <volume>16</volume>
                  <issue>4</issue>
                  <fpage>1340</fpage>
                  <lpage>1349</lpage>
                  <?supplied-pmid 9552035?>
                  <pub-id pub-id-type="pmid">9552035</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yamashita</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Ogawa</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Yamashita</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Nomura</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Kuramoto</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Saishoji</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Shin</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer</article-title>
                  <source>Cancer Res</source>
                  <year>1994</year>
                  <volume>54</volume>
                  <issue>7</issue>
                  <fpage>1630</fpage>
                  <lpage>1633</lpage>
                  <?supplied-pmid 8137271?>
                  <pub-id pub-id-type="pmid">8137271</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Graveel</surname>
                      <given-names>CR</given-names>
                    </name>
                    <name>
                      <surname>DeGroot</surname>
                      <given-names>JD</given-names>
                    </name>
                    <name>
                      <surname>Su</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Koeman</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Dykema</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Leung</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Snider</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Davies</surname>
                      <given-names>SR</given-names>
                    </name>
                    <name>
                      <surname>Swiatek</surname>
                      <given-names>PJ</given-names>
                    </name>
                    <name>
                      <surname>Cottingham</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Watson</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Ellis</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Sigler</surname>
                      <given-names>RE</given-names>
                    </name>
                    <name>
                      <surname>Furge</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>Vande Woude</surname>
                      <given-names>GF</given-names>
                    </name>
                  </person-group>
                  <article-title>Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer</article-title>
                  <source>Proc Natl Acad Sci U S A</source>
                  <year>2009</year>
                  <volume>106</volume>
                  <issue>31</issue>
                  <fpage>12909</fpage>
                  <lpage>12914</lpage>
                  <pub-id pub-id-type="doi">10.1073/pnas.0810403106</pub-id>
                  <?supplied-pmid 19567831?>
                  <pub-id pub-id-type="pmid">19567831</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ponzo</surname>
                      <given-names>MG</given-names>
                    </name>
                    <name>
                      <surname>Lesurf</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Petkiewicz</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>O’Malley</surname>
                      <given-names>FP</given-names>
                    </name>
                    <name>
                      <surname>Pinnaduwage</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Andrulis</surname>
                      <given-names>IL</given-names>
                    </name>
                    <name>
                      <surname>Bull</surname>
                      <given-names>SB</given-names>
                    </name>
                    <name>
                      <surname>Chughtai</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Zuo</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Souleimanova</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Germain</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Omeroglu</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Cardiff</surname>
                      <given-names>RD</given-names>
                    </name>
                    <name>
                      <surname>Hallett</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Park</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer</article-title>
                  <source>Proc Natl Acad Sci U S A</source>
                  <year>2009</year>
                  <volume>106</volume>
                  <issue>31</issue>
                  <fpage>12903</fpage>
                  <lpage>12908</lpage>
                  <pub-id pub-id-type="doi">10.1073/pnas.0810402106</pub-id>
                  <?supplied-pmid 19617568?>
                  <pub-id pub-id-type="pmid">19617568</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rosen</surname>
                      <given-names>LS</given-names>
                    </name>
                    <name>
                      <surname>Senzer</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Mekhail</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Ganapathi</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Chai</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Savage</surname>
                      <given-names>RE</given-names>
                    </name>
                    <name>
                      <surname>Waghorne</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Abbadessa</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Schwartz</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Dreicer</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <article-title>A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors</article-title>
                  <source>Clin Cancer Res</source>
                  <year>2011</year>
                  <volume>17</volume>
                  <issue>24</issue>
                  <fpage>7754</fpage>
                  <lpage>7764</lpage>
                  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-1002</pub-id>
                  <?supplied-pmid 21976535?>
                  <pub-id pub-id-type="pmid">21976535</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Santoro</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Rimassa</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Borbath</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Daniele</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Salvagni</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Van Laethem</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Van Vlierberghe</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Trojan</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Kolligs</surname>
                      <given-names>FT</given-names>
                    </name>
                    <name>
                      <surname>Weiss</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Miles</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Gasbarrini</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Lencioni</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Cicalese</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Sherman</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Gridelli</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Buggisch</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Gerken</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Schmid</surname>
                      <given-names>RM</given-names>
                    </name>
                    <name>
                      <surname>Boni</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Personeni</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Hassoun</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Abbadessa</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Schwartz</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Von Roemeling</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Lamar</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Porta</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study</article-title>
                  <source>Lancet Oncol</source>
                  <year>2013</year>
                  <volume>14</volume>
                  <issue>1</issue>
                  <fpage>55</fpage>
                  <lpage>63</lpage>
                  <pub-id pub-id-type="doi">10.1016/S1470-2045(12)70490-4</pub-id>
                  <?supplied-pmid 23182627?>
                  <pub-id pub-id-type="pmid">23182627</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sequist</surname>
                      <given-names>LV</given-names>
                    </name>
                    <name>
                      <surname>von Pawel</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Garmey</surname>
                      <given-names>EG</given-names>
                    </name>
                    <name>
                      <surname>Akerley</surname>
                      <given-names>WL</given-names>
                    </name>
                    <name>
                      <surname>Brugger</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Ferrari</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Costa</surname>
                      <given-names>DB</given-names>
                    </name>
                    <name>
                      <surname>Gerber</surname>
                      <given-names>DE</given-names>
                    </name>
                    <name>
                      <surname>Orlov</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Ramlau</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Arthur</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Gorbachevsky</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Schwartz</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Schiller</surname>
                      <given-names>JH</given-names>
                    </name>
                  </person-group>
                  <article-title>Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer</article-title>
                  <source>J Clin Oncol</source>
                  <year>2011</year>
                  <volume>29</volume>
                  <issue>24</issue>
                  <fpage>3307</fpage>
                  <lpage>3315</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2010.34.0570</pub-id>
                  <?supplied-pmid 21768463?>
                  <pub-id pub-id-type="pmid">21768463</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yap</surname>
                      <given-names>TA</given-names>
                    </name>
                    <name>
                      <surname>Olmos</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Brunetto</surname>
                      <given-names>AT</given-names>
                    </name>
                    <name>
                      <surname>Tunariu</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Barriuso</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Riisnaes</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Pope</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Clark</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Futreal</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Germuska</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Collins</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>deSouza</surname>
                      <given-names>NM</given-names>
                    </name>
                    <name>
                      <surname>Leach</surname>
                      <given-names>MO</given-names>
                    </name>
                    <name>
                      <surname>Savage</surname>
                      <given-names>RE</given-names>
                    </name>
                    <name>
                      <surname>Waghorne</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Chai</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Garmey</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Schwartz</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Kaye</surname>
                      <given-names>SB</given-names>
                    </name>
                    <name>
                      <surname>de Bono</surname>
                      <given-names>JS</given-names>
                    </name>
                  </person-group>
                  <article-title>Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies</article-title>
                  <source>J Clin Oncol</source>
                  <year>2011</year>
                  <volume>29</volume>
                  <issue>10</issue>
                  <fpage>1271</fpage>
                  <lpage>1279</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2010.31.0367</pub-id>
                  <?supplied-pmid 21383285?>
                  <pub-id pub-id-type="pmid">21383285</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McClelland</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>Finlay</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Walker</surname>
                      <given-names>KJ</given-names>
                    </name>
                    <name>
                      <surname>Nicholson</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Robertson</surname>
                      <given-names>JF</given-names>
                    </name>
                    <name>
                      <surname>Blamey</surname>
                      <given-names>RW</given-names>
                    </name>
                    <name>
                      <surname>Nicholson</surname>
                      <given-names>RI</given-names>
                    </name>
                  </person-group>
                  <article-title>Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer</article-title>
                  <source>Cancer Res</source>
                  <year>1990</year>
                  <volume>50</volume>
                  <issue>12</issue>
                  <fpage>3545</fpage>
                  <lpage>3550</lpage>
                  <?supplied-pmid 2187598?>
                  <pub-id pub-id-type="pmid">2187598</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Van Allen</surname>
                      <given-names>EM</given-names>
                    </name>
                    <name>
                      <surname>Wagle</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Stojanov</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Perrin</surname>
                      <given-names>DL</given-names>
                    </name>
                    <name>
                      <surname>Cibulskis</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Marlow</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Jane-Valbuena</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Friedrich</surname>
                      <given-names>DC</given-names>
                    </name>
                    <name>
                      <surname>Kryukov</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Carter</surname>
                      <given-names>SL</given-names>
                    </name>
                    <name>
                      <surname>McKenna</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Sivachenko</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Rosenberg</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Kiezun</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Voet</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Lawrence</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Lichtenstein</surname>
                      <given-names>LT</given-names>
                    </name>
                    <name>
                      <surname>Gentry</surname>
                      <given-names>JG</given-names>
                    </name>
                    <name>
                      <surname>Huang</surname>
                      <given-names>FW</given-names>
                    </name>
                    <name>
                      <surname>Fostel</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Farlow</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Barbie</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Gandhi</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Lander</surname>
                      <given-names>ES</given-names>
                    </name>
                    <name>
                      <surname>Gray</surname>
                      <given-names>SW</given-names>
                    </name>
                    <name>
                      <surname>Joffe</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Janne</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Garber</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>MacConaill</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Lindeman</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Rollins</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Kantoff</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Fisher</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Gabriel</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Getz</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Garraway</surname>
                      <given-names>LA</given-names>
                    </name>
                  </person-group>
                  <article-title>Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine</article-title>
                  <source>Nat Med</source>
                  <year>2014</year>
                  <volume>20</volume>
                  <issue>6</issue>
                  <fpage>682</fpage>
                  <lpage>688</lpage>
                  <pub-id pub-id-type="doi">10.1038/nm.3559</pub-id>
                  <?supplied-pmid 24836576?>
                  <pub-id pub-id-type="pmid">24836576</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cibulskis</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Lawrence</surname>
                      <given-names>MS</given-names>
                    </name>
                    <name>
                      <surname>Carter</surname>
                      <given-names>SL</given-names>
                    </name>
                    <name>
                      <surname>Sivachenko</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Jaffe</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Sougnez</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Gabriel</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Meyerson</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Lander</surname>
                      <given-names>ES</given-names>
                    </name>
                    <name>
                      <surname>Getz</surname>
                      <given-names>G</given-names>
                    </name>
                  </person-group>
                  <article-title>Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples</article-title>
                  <source>Nat Biotechnol</source>
                  <year>2013</year>
                  <volume>31</volume>
                  <issue>3</issue>
                  <fpage>213</fpage>
                  <lpage>219</lpage>
                  <pub-id pub-id-type="doi">10.1038/nbt.2514</pub-id>
                  <?supplied-pmid 23396013?>
                  <pub-id pub-id-type="pmid">23396013</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Michieli</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Di Nicolantonio</surname>
                      <given-names>F</given-names>
                    </name>
                  </person-group>
                  <article-title>Targeted therapies: tivantinib--a cytotoxic drug in MET inhibitor’s clothes?</article-title>
                  <source>Nat Rev Clin Oncol</source>
                  <year>2013</year>
                  <volume>10</volume>
                  <issue>7</issue>
                  <fpage>372</fpage>
                  <lpage>374</lpage>
                  <pub-id pub-id-type="doi">10.1038/nrclinonc.2013.86</pub-id>
                  <?supplied-pmid 23712183?>
                  <pub-id pub-id-type="pmid">23712183</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Goyal</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Muzumdar</surname>
                      <given-names>MD</given-names>
                    </name>
                    <name>
                      <surname>Zhu</surname>
                      <given-names>AX</given-names>
                    </name>
                  </person-group>
                  <article-title>Targeting the HGF/c-MET pathway in hepatocellular carcinoma</article-title>
                  <source>Clin Cancer Res</source>
                  <year>2013</year>
                  <volume>19</volume>
                  <issue>9</issue>
                  <fpage>2310</fpage>
                  <lpage>2318</lpage>
                  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-2791</pub-id>
                  <?supplied-pmid 23388504?>
                  <pub-id pub-id-type="pmid">23388504</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Scagliotti</surname>
                      <given-names>GV</given-names>
                    </name>
                    <name>
                      <surname>Novello</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Schiller</surname>
                      <given-names>JH</given-names>
                    </name>
                    <name>
                      <surname>Hirsh</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Sequist</surname>
                      <given-names>LV</given-names>
                    </name>
                    <name>
                      <surname>Soria</surname>
                      <given-names>JC</given-names>
                    </name>
                    <name>
                      <surname>von Pawel</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Schwartz</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Von Roemeling</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Sandler</surname>
                      <given-names>AB</given-names>
                    </name>
                  </person-group>
                  <article-title>Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer</article-title>
                  <source>Clin Lung Cancer</source>
                  <year>2012</year>
                  <volume>13</volume>
                  <issue>5</issue>
                  <fpage>391</fpage>
                  <lpage>395</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.cllc.2012.01.003</pub-id>
                  <?supplied-pmid 22440336?>
                  <pub-id pub-id-type="pmid">22440336</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <mixed-citation publication-type="other">
                  <ext-link ext-link-type="uri" xlink:href="http://productlibrary.ventanamed.com">http://productlibrary.ventanamed.com</ext-link>
                </mixed-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <mixed-citation publication-type="other">Diéras V, Yardley DA., Romieu G, Valero V, Isakoff SJ, Koeppen H, Thurm H, Mocci S, Teng SLM, Campone M (2013) A randomized, phase II, multicenter, double-blind, placebo-controlled trial evaluating onartuzumab with or without bevacizumab in combination with weekly paclitaxel in locally recurrent or metastatic triple-negative breast cancer (TNBC). San Antonio Breast Conference, Abstract p 2-16-01</mixed-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Basilico</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Pennacchietti</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Vigna</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Chiriaco</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Arena</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Bardelli</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Valdembri</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Serini</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Michieli</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET</article-title>
                  <source>Clin Cancer Res</source>
                  <year>2013</year>
                  <volume>19</volume>
                  <issue>9</issue>
                  <fpage>2381</fpage>
                  <lpage>2392</lpage>
                  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-3459</pub-id>
                  <?supplied-pmid 23532890?>
                  <pub-id pub-id-type="pmid">23532890</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Katayama</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Aoyama</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Yamori</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Qi</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Oh-hara</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Song</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Engelman</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Fujita</surname>
                      <given-names>N</given-names>
                    </name>
                  </person-group>
                  <article-title>Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition</article-title>
                  <source>Cancer Res</source>
                  <year>2013</year>
                  <volume>73</volume>
                  <issue>10</issue>
                  <fpage>3087</fpage>
                  <lpage>3096</lpage>
                  <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-3256</pub-id>
                  <?supplied-pmid 23598276?>
                  <pub-id pub-id-type="pmid">23598276</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Calles</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Kwiatkowski</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Cammarata</surname>
                      <given-names>BK</given-names>
                    </name>
                    <name>
                      <surname>Ercan</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Gray</surname>
                      <given-names>NS</given-names>
                    </name>
                    <name>
                      <surname>Janne</surname>
                      <given-names>PA</given-names>
                    </name>
                  </person-group>
                  <article-title>Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines</article-title>
                  <source>Mol Oncol</source>
                  <year>2015</year>
                  <volume>9</volume>
                  <issue>1</issue>
                  <fpage>260</fpage>
                  <lpage>269</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.molonc.2014.08.011</pub-id>
                  <?supplied-pmid 25226813?>
                  <pub-id pub-id-type="pmid">25226813</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
